JAMA Intern Med

Integrated care model most effective for smoking cessation in the setting of lung cancer screening

January 15, 2025

Study details: This randomized trial evaluated the efficacy of three smoking cessation strategies among 630 current smokers eligible for lung cancer screening. Participants were randomized into three groups: (1) quitline referral and nicotine replacement therapy (QL), (2) quitline referral with nicotine replacement therapy or medication prescribed by a lung cancer screening clinician (QL+), and (3) integrated care involving nicotine replacement therapy or prescription pharmacotherapy and counseling (IC). The study was conducted from July 2017 to June 2022 at a hospital-based tobacco treatment clinic in Houston, Texas.

Results: The IC model demonstrated the highest smoking cessation rates at six months compared with the other two groups (IC: 32.4%, QL+: 27.6%, and QL: 20.5%). Participants in the IC group had significantly higher self-reported abstinence rates.

Clinical impact: These findings suggest that integrated care models, combining pharmacotherapy and counseling, are the most effective smoking cessation interventions in lung cancer screening settings.

Source:

Cinciripini PM, et al. (2025, January 13). JAMA Intern Med. Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39804633/